$PIRS
Pieris Pharmaceuticals Inc

2023 Q3 Form 10-Q Financial Statement

#000143774923023085 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $19.52M $20.06M
YoY Change 263.5% 442.32%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.840M $3.664M
YoY Change 73.21% -10.22%
% of Gross Profit
Research & Development $9.595M $14.33M
YoY Change -29.39% 19.93%
% of Gross Profit
Depreciation & Amortization $740.0K $758.0K
YoY Change -3.52% 30.02%
% of Gross Profit
Operating Expenses $31.33M $17.99M
YoY Change 78.62% 12.25%
Operating Profit -$11.81M $2.063M
YoY Change -2.97% -116.73%
Interest Expense $549.0K $490.0K
YoY Change 127.8% 271.21%
% of Operating Profit 23.75%
Other Income/Expense, Net $506.0K -$161.0K
YoY Change -30.01% -123.82%
Pretax Income -$10.75M $3.976M
YoY Change 10.41% -138.46%
Income Tax
% Of Pretax Income
Net Earnings -$10.80M $3.976M
YoY Change 11.34% -138.6%
Net Earnings / Revenue -55.33% 19.83%
Basic Earnings Per Share -$0.11 $0.05
Diluted Earnings Per Share -$0.11 $0.05
COMMON SHARES
Basic Shares Outstanding 98.85M 82.02M
Diluted Shares Outstanding 1.236M 87.83M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $44.80M $54.88M
YoY Change -35.84% -32.2%
Cash & Equivalents $32.89M $44.94M
Short-Term Investments $11.90M $9.937M
Other Short-Term Assets $13.30M $10.65M
YoY Change 68.18% 22.3%
Inventory
Prepaid Expenses
Receivables $1.045M $952.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $59.09M $66.47M
YoY Change -24.78% -26.88%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $16.16M
YoY Change -100.0% -7.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $287.0K $1.093M
YoY Change -78.04% -53.65%
Total Long-Term Assets $287.0K $21.07M
YoY Change -98.61% -9.97%
TOTAL ASSETS
Total Short-Term Assets $59.09M $66.47M
Total Long-Term Assets $287.0K $21.07M
Total Assets $59.38M $87.54M
YoY Change -40.12% -23.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.816M $7.604M
YoY Change -22.66% 300.63%
Accrued Expenses $24.50M $8.585M
YoY Change 115.25% -15.63%
Deferred Revenue $994.0K $17.68M
YoY Change -94.63% -22.66%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $28.87M $34.37M
YoY Change -13.89% -3.31%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.87M $34.37M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $28.87M $47.05M
YoY Change -54.47% -32.74%
SHAREHOLDERS EQUITY
Retained Earnings -$310.4M -$299.6M
YoY Change 9.95% 9.9%
Common Stock $99.00K $99.00K
YoY Change 33.78% -99.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $30.51M $40.50M
YoY Change
Total Liabilities & Shareholders Equity $59.38M $87.54M
YoY Change -40.12% -23.41%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$10.80M $3.976M
YoY Change 11.34% -138.6%
Depreciation, Depletion And Amortization $740.0K $758.0K
YoY Change -3.52% 30.02%
Cash From Operating Activities -$9.720M -$13.43M
YoY Change 10.73% -13.78%
INVESTING ACTIVITIES
Capital Expenditures $60.00K $67.00K
YoY Change -276.47% -110.65%
Acquisitions
YoY Change
Other Investing Activities -$1.910M -$1.299M
YoY Change -134.7% -87.31%
Cash From Investing Activities -$1.990M -$1.366M
YoY Change -136.38% -87.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 19.78M
YoY Change -100.0% 6939.5%
NET CHANGE
Cash From Operating Activities -9.720M -13.43M
Cash From Investing Activities -1.990M -1.366M
Cash From Financing Activities 0.000 19.78M
Net Change In Cash -11.71M 4.984M
YoY Change 286.98% -119.05%
FREE CASH FLOW
Cash From Operating Activities -$9.720M -$13.43M
Capital Expenditures $60.00K $67.00K
Free Cash Flow -$9.780M -$13.50M
YoY Change 11.85% -9.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
700000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
700000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
CY2021Q2 us-gaap Grants Receivable
GrantsReceivable
14200000 eur
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
98851927
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
74519103
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
15617
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
15617
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
15617
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37471
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
30-0784346
dei Entity Address Address Line1
EntityAddressAddressLine1
225 Franklin Street, 26th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02110
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
246-8998
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
PIRS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
98851927
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44938000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38635000 usd
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
9937000 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
20534000 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
952000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5810000 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10645000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8445000 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
66472000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
73424000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16163000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16992000 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3816000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3705000 usd
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1093000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1369000 usd
CY2023Q2 us-gaap Assets
Assets
87544000 usd
CY2022Q4 us-gaap Assets
Assets
95490000 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
7604000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4154000 usd
CY2023Q2 pirs Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
9082000 usd
CY2022Q4 pirs Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
11605000 usd
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
17683000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
20824000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
34369000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36583000 usd
CY2023Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
759000 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
18734000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11918000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12244000 usd
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 usd
CY2023Q2 us-gaap Liabilities
Liabilities
47046000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
67561000 usd
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
99000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
74000 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
340164000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
318530000 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-137000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-254000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-299628000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-290421000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
40498000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
171000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
72000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
152000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4265000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10666000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9090000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
27929000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
87544000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95490000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
20086000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3468000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
22096000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14647000 usd
CY2023Q2 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
-31000 usd
CY2022Q2 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
230000 usd
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
-105000 usd
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
39000 usd
CY2023Q2 us-gaap Revenues
Revenues
20055000 usd
CY2022Q2 us-gaap Revenues
Revenues
3698000 usd
us-gaap Revenues
Revenues
21991000 usd
us-gaap Revenues
Revenues
14686000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14328000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11947000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27752000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26013000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3664000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4081000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7687000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8460000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
17992000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
16028000 usd
us-gaap Operating Expenses
OperatingExpenses
35439000 usd
us-gaap Operating Expenses
OperatingExpenses
34473000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
2063000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12330000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-13448000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-19787000 usd
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
490000 usd
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
132000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
847000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
129000 usd
CY2023Q2 us-gaap Government Assistance Amount
GovernmentAssistanceAmount
1584000 usd
CY2022Q2 us-gaap Government Assistance Amount
GovernmentAssistanceAmount
1184000 usd
us-gaap Government Assistance Amount
GovernmentAssistanceAmount
3612000 usd
us-gaap Government Assistance Amount
GovernmentAssistanceAmount
3314000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-161000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
676000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-218000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
905000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
3976000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10338000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9207000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15439000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
287000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-499000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
45000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-356000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15643000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87639000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74125000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
81115000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73919000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
87826000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74125000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81115000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73919000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
53450000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10338000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-499000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
171000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1301000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
104000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
15458000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
3976000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
287000 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1048000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
52000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
40498000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
50755000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15439000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-356000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
152000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2479000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
95000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
104000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
27929000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9207000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
45000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
72000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1932000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
52000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
40498000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9207000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15439000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1363000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1428000 usd
pirs Operating Lease Right Of Use Asset Accretion
OperatingLeaseRightOfUseAssetAccretion
67000 usd
pirs Operating Lease Right Of Use Asset Accretion
OperatingLeaseRightOfUseAssetAccretion
5000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1932000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2479000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
53000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-40000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
110000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-214000 usd
us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
18285000 usd
us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
26938000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24427000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38221000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
115000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1018000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
18895000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
4850000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
8243000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
31645000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10537000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27813000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
95000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
52000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
104000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19729000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6640000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19781000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6839000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
412000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-4312000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6303000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-63507000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38635000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
117764000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
44938000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
54257000 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
72000 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
152000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
74000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
15000 usd
CY2023Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
54900000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
4000000.0 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10300000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-299600000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Basis of Presentation and Use of Estimates</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying condensed consolidated financial statements of Pieris Pharmaceuticals, Inc. and its wholly-owned subsidiaries were prepared in accordance with U.S. GAAP. The condensed consolidated financial statements include the accounts of all subsidiaries. All intercompany balances and transactions have been eliminated.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are <em style="font: inherit;">not</em> limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; determination of the incremental borrowing rate to calculate right-of-use assets and lease liabilities; beneficial conversion features; fair value of stock options, preferred stock, and warrants; and prepaid and accrued clinical trial expenses. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management’s estimates, judgments and assumptions.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Concentration of Credit Risk and Off-Balance Sheet Risk</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has <em style="font: inherit;">no</em> financial instruments with off-balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments, and accounts receivable. The Company’s cash, cash equivalents, and investments are held in accounts with financial institutions that management believes are creditworthy. The Company’s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimize the exposure to concentration of credit risk. The Company has <em style="font: inherit;">not</em> experienced any credit losses in such accounts and does <em style="font: inherit;">not</em> believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does <em style="font: inherit;">not</em> obtain collateral.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p>
CY2023Q2 us-gaap Revenues
Revenues
20055000 usd
CY2022Q2 us-gaap Revenues
Revenues
3698000 usd
us-gaap Revenues
Revenues
21991000 usd
us-gaap Revenues
Revenues
14686000 usd
CY2023Q2 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
CY2023Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
19900000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
21600000 usd
CY2021Q2 us-gaap Grants Receivable
GrantsReceivable
17000000.0 usd
CY2023Q2 pirs Cash Equivalents And Investments
CashEquivalentsAndInvestments
46642000 usd
CY2022Q4 pirs Cash Equivalents And Investments
CashEquivalentsAndInvestments
38152000 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
9938000 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000 usd
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
9937000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
-100000 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
26684000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
26639000 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10521000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9647000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16163000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16992000 usd
CY2023Q2 pirs Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
3847000 usd
CY2022Q4 pirs Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
5758000 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2125000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3015000 usd
CY2023Q2 pirs Accrued Accounts Payable Current
AccruedAccountsPayableCurrent
1531000 usd
CY2022Q4 pirs Accrued Accounts Payable Current
AccruedAccountsPayableCurrent
1245000 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
497000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
483000 usd
CY2023Q2 pirs Accrued Collaboration Costs Current
AccruedCollaborationCostsCurrent
172000 usd
CY2022Q4 pirs Accrued Collaboration Costs Current
AccruedCollaborationCostsCurrent
245000 usd
CY2023Q2 pirs Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
9082000 usd
CY2022Q4 pirs Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
11605000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
3976000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10338000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9207000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15439000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87639000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74125000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
81115000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73919000
CY2023Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
187000
CY2022Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
87826000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74125000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81115000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73919000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
41200000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
39600000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
98851927
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
74519103
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
15617
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
287000 usd
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
331000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
574000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
680000 usd
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
204000 usd
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
165000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
388000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
324000 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
491000 usd
CY2022Q2 us-gaap Lease Cost
LeaseCost
496000 usd
us-gaap Lease Cost
LeaseCost
962000 usd
us-gaap Lease Cost
LeaseCost
1004000 usd
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y1M6D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.105 pure
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
500000 usd
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
600000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1070000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2141000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2141000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2141000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2141000 usd
CY2023Q2 pirs Lessee Operating Lease Liability To Be Paid Due After Year Four
LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour
9812000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
19446000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6619000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
12827000 usd

Files In Submission

Name View Source Status
0001437749-23-023085-index-headers.html Edgar Link pending
0001437749-23-023085-index.html Edgar Link pending
0001437749-23-023085.txt Edgar Link pending
0001437749-23-023085-xbrl.zip Edgar Link pending
ex_531047.htm Edgar Link pending
ex_531048.htm Edgar Link pending
ex_531049.htm Edgar Link pending
ex_531050.htm Edgar Link pending
ex_555614.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pirs-20230630.xsd Edgar Link pending
pirs20230607_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
pirs-20230630_def.xml Edgar Link unprocessable
pirs-20230630_lab.xml Edgar Link unprocessable
pirs-20230630_pre.xml Edgar Link unprocessable
pirs20230607_10q_htm.xml Edgar Link completed
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
pirs-20230630_cal.xml Edgar Link unprocessable